



Nicox: Publication of shareholder presentation of October 10, 2014

October 10, 2014.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) is organizing today, October 10, 2014, a briefing meeting for its shareholders in Paris at 12.00 pm CET. The presentation will be available by 10.00 am CET in the 'News & Media' / 'Presentations & Webcasts' section of Nicox's website (www.nicox.com).

This presentation will be a general update on Nicox's activities, the proposed acquisition of Acix Therapeutics, Inc. and will also include additional information on the financial terms related to VESNEO (latanoprostene bunod), subject to the achievement of certain milestones.

A live webcast will be available at <http://www.media-server.com/m/p/pfvgqngw>.

A recording will be available by 6.00 pm CET at <http://www.media-server.com/m/p/pfvgqngw>.

About Nicox



Nicox (Bloomberg: COX.FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014, in the "Rapport semestriel financier et d'activité au 30 juin 2014" and in the 5th chapter of the "Actualisation du Document de Référence 2013" filed on September 30, 2014 (D. 14-0271-A01), available on Nicox's website (www.nicox.com).

.....

Contacts



Nicox

Gavin Spencer | Executive Vice President Corporate Development
+33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom

Jonathan Birt
+44 7860 361 746 | jonathan.birt@ymail.com

France

Caroline Courme | Communication Manager
+33 (0)4 97 24 53 43 | courme@nicox.com